<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7029664/results/search/drug/results.xml">
  <result pre="thyroid dysfunction in children with HCV infection receiving PegIFN plus" exact="ribavirin" post="and showed that 28% of children (14 of 50)"/>
  <result pre="still widely used for treating children worldwide. Although PegIFN plus" exact="ribavirin" post="is approved for children with HCV infection (age ≥3"/>
  <result pre="Hepatol201052501720189674 5RashedYKKhalafFAKotbSEThyroid disturbances in children treated with combined Pegylated Interferon" exact="alpha" post="and Ribavirin for chronic hepatitis CClin Exp Pediatr20206352532024338 6MandacJCChaudhrySShermanKETomerYThe"/>
  <result pre="disturbances in children treated with combined Pegylated Interferon alpha and" exact="Ribavirin" post="for chronic hepatitis CClin Exp Pediatr20206352532024338 6MandacJCChaudhrySShermanKETomerYThe clinical and"/>
  <result pre="and risk factors for thyroid dysfunction during peginterferon α and" exact="ribavirin" post="treatment in patients with chronic hepatitis CKorean J Intern"/>
  <result pre="https://www.hcvguidelines.org Table 1. Comparison of direct-acting antiviral and peginterferon plus" exact="ribavirin" post="in children Variable DAA PegIFN + ribavirin Administration Oral"/>
  <result pre="and peginterferon plus ribavirin in children Variable DAA PegIFN +" exact="ribavirin" post="Administration Oral PegIFN: subcutaneous injection (per week) Ribavirin: oral"/>
  <result pre="100% Genotype 1: 53%; Genotype 2, 3: 93% Available age" exact="Sofosbuvir" post="or ledipasvir/sofosbuvir ≥12 years (European Medicines Agency), ≥3 years"/>
 </snippets>
</snippetsTree>
